Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
NCT02227394
Asthma, Asthma Bronchial
Edegem, Antwerp, Belgium
View Trial DetailsNCT Number: NCT00531414
The OsmohalerTM is a registered device in Australia. It is used to deliver a dry powder a commercial preparation of mannitol registered as AridolTM to test if a person has irritable airways such as active asthma.
The overseas regulatory authorities need to know that people of all ages can achieve an adequate inspiratory flow through this device during a controlled deep inspiration. Adequate flow is generally regarded as greater than 30 litres per minute in children and 60 litres per minute in adults. The OsmohalerTM is a device with low resistance and is already in use in Australia to deliver mannitol. However there is a need to document inspiratory flows through the device during a controlled deep inspiration. The protocol requires subjects to perform a controlled deep inspiration from the device on three or five occasions. No substance will be inhaled.
Looking for future studies?
Notify Me6 year–69 year
All sexes
Observational
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Looking for future studies?
Notify MeSyntara
Industry
Inspiratory Flow and VOlumes in Asthmatic and Healthy Individuals Using the Osmohaler
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02227394
Asthma, Asthma Bronchial
Edegem, Antwerp, Belgium
View Trial DetailsNCT02809560
Asthma, Bronchial Diseases
Toulouse, France
View Trial DetailsNCT05091034
Asthma, Bronchial Diseases
New York, United States
View Trial DetailsNCT05853809
Asthma, Bronchial Diseases
Stockholm, Sweden
View Trial Details